Modulation of the interleukin-6 signalling pathway and incidence rates of atherosclerotic events and all-cause mortality: analyses from the Canakinumab Anti-Inflammatory Thrombosis Outcomes Study (CANTOS)

Abstract Aims Canakinumab, a monoclonal antibody targeting interleukin (IL)-1β, reduces rates of recurrent cardiovascular events without lowering lipids. It is uncertain, however, to what extent these beneficial cardiovascular outcomes are mediated through interleukin-6 (IL-6) signalling, an issue w...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	European heart journal 2018-10, Vol.39 (38), p.3499-3507
Hauptverfasser:	Ridker, Paul M, Libby, Peter, MacFadyen, Jean G, Thuren, Tom, Ballantyne, Christie, Fonseca, Francisco, Koenig, Wolfgang, Shimokawa, Hiroaki, Everett, Brendan M, Glynn, Robert J
Format:	Artikel
Sprache:	eng
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!